AMITRIPTYLINE
SIVEM PHARMACEUTICALS ULC
This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.
Quick answers
Is AMITRIPTYLINE discontinued in Canada?
Yes. The manufacturer has reported to Health Canada that AMITRIPTYLINE 25MG has been permanently discontinued (last updated September 18, 2019). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.
Why is AMITRIPTYLINE not available?
The reason the manufacturer reported: Business reasons.
Other Products Containing the Same Active Ingredient
These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.
Closest Matches
MAR-AMITRIPTYLINE
MARCAN PHARMACEUTICALS INC
Other Products
PMS-AMITRIPTYLINE
PHARMASCIENCE INC
PRO-AMITRIPTYLINE
PRO DOC LIMITEE
JAMP-AMITRIPTYLINE
JAMP PHARMA CORPORATION
What this means
Does this mean I need to switch medications right away?
Not necessarily right away, but this product will not be returning to the market.
What should I do?
Talk to your pharmacist or prescriber about your options well before your current supply runs out.
⚠ Possible Recall or Safety Alert
Health Canada has issued a recall or safety alert matching this product. This match is based on product name similarity and may not be exact — confirm against your specific lot number before taking action.
Apo-Amitriptyline
Apo-Amitriptyline: Affected lots may exceed the interim acceptable intake limit for NNORT
Highest health risk
Possible match — not confirmed
AMITRIPTYLINE 10 & 50mg
AMITRIPTYLINE 10 & 50mg: NDMA and NNORT impurity
Highest health risk
Possible match — not confirmed
APO-AMITRIPTYLINE Tablets
APO-AMITRIPTYLINE Tablets: NNORT impurity
Highest health risk
Possible match — not confirmed
APO-AMITRIPTYLINE 10mg
APO-AMITRIPTYLINE 10mg: NDMA Impurity
Highest health risk
Possible match — not confirmed
APO-AMITRIPTYLINE 10mg
APO-AMITRIPTYLINE 10mg: NDMA impurity
Highest health risk
Possible match — not confirmed
DIN
02451794
Strength
25MG
Dosage Form
TABLET
Route
ORAL
Compare with another product →
Shortage History
Other Products from SIVEM PHARMACEUTICALS ULC
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
70MG · DIN 02299712
10MG · DIN 02447576
200MG · DIN 02385465
10MG · DIN 02451786
50MG · DIN 02451808
10MG · DIN 02385805
5MG · DIN 02385791
2.5MG · DIN 02385783
500MG · DIN 02401509
250MG · DIN 02401495
250MG · DIN 02401541
250MG · DIN 02401576